References
1. Ametov A.S., Gusenbekova D.G. Effect of dipeptidyl peptidase-4 inhibitors in combination with metformin on carbohydrate and fat metabolism in patients with type 2 diabetes mellitus and obesity. Lechenie i profilaktika [Disease Treatment and Prevention]. 2015; 2 (14): 47–52. (in Russian)
2. Sun H. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.
3. Diabetes mellitus type 2. Problems and Solutions. 3rd ed., revised and expanded. Vol. 1. In: A.S. Ametov (ed.). Moscow: GEOTAR-Media, 2015: 90–119. (in Russian)
4. Kloppel G., Lohr M., Oberholzer M., Heitz P.I. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res. 1985; 4: 110–25.
5. Butler A.E., Janson J., Bonner-Weir S., et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52 (1): 102–10.
6. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care. 2007; 30 (6): 1335–43.
7. Kononenko I.V., Smirnova O.M. Diabetes mellitus: from understanding the etiology to the choice of treatment. Farmateka [Pharmateca]. 2014; (5): 86–93. (in Russian)
8. Instructions for medical use of the medicinal product Janumet, taking into account changes in 1 Registration Certificate LP 000046-221110 dated 22.11.2010. (in Russian)
9. Hattori S. Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2021; 13: 1–7.
10. Aschner P., Kipnes M., Lunceford J., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29 (12): 2632–7.
11. Scott L. Sitagliptin: A review in type 2 diabetes. Drugs. 2017; 77: 209–24.
12. Hartley P., Shentu Y., Betz-Schiff P., Golm G. Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: A randomized, double-blind, non-inferiority trial. Drugs Aging. 2015; 32: 469–76.
13. Barzilai N., Guo H., Mahoney E., Caporossi S. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011; 27 (5): 1049–58.
14. Arjona Ferreira J.C., Marre M., Barzilai N., Guo H. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013; 36 (5): 1067–73.
15. Kothny W., Lukashevich V., Foley J., Rendell E. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: A randomised clinical trial. Diabetologia. 2015; 58: 2020–6.
16. Arjona Ferreira J.C., Corry D., Mogensen C.E., Sloan L. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial. Am J Kidney Dis. 2013; 61 (4): 579–87.
17. Messori A. Testing the therapeutic equivalence of alogliptin, linagliptin, saxagliptin, sitagliptin or vildagliptin as monotherapy or in combination with metformin in patients with type 2 diabetes. Diabetes Ther. 2014; 5 (1): 341–4.
18. Instruction for medical usage of the drug Sitadiab®. LP-No.(000724)-(RG-RU)-220422. (in Russian)